May 1, 2020. A dermatology resident in North Carolina downloads TikTok during COVID lockdown. The clinic is slow. He posts a video as a joke.

Five years later: 20 million followers. A skincare brand doing $50M in projected 2026 revenue. A $20M Series A led by L Catterton.

Dr. Muneeb Shah started with medical humor,day-in-the-life content for healthcare professionals. Then he noticed the rampant skincare misinformation flooding the platform and pivoted to debunking it. A video called "Worst Skin Care Trends" went mega-viral, 15 million views in a single day. He kept going. Five years of consistent, science-first education to an audience that trusted him precisely because he wasn't selling anything.

Then he decided to build something worth selling.

Remedy launches March 2024. Formulas targeting the body complaints that cosmetic brands consistently ignore: strawberry skin, dark spots, pore size, extreme dryness. DTC, Amazon, TikTok Shop, Target. He doesn't go Sephora, the mass accessibility is deliberate.

The result: science-backed meets creator-led, two of the most powerful consumer forces in beauty right now, producing $50M in projected 2026 revenue within two years of launch.

L Catterton has now backed two expert-led beauty brands in the same week, Remedy and Rōz.

Mara Roszak spent two decades styling the most photographed hair in Hollywood. Emma Stone. Natalie Portman. Nicole Kidman. Zoe Saldaña.

On set, she kept running into the same problem. Most clean brands sacrificed performance. Most professional-grade brands used silicones and chemicals she didn't want on her clients. The product she needed didn't exist, so she built it.

She tests lab samples on Emma Stone and Michelle Yeoh at the Oscars. The highest-stakes environment possible as the QA process. Not a focus group. Not a survey. The actual event where a hair failure gets photographed by 500 cameras.

Rōz is founded in 2021. The seed round comes from celebrity hair stylist and makeup artist friends who can introduce A-list clients, and from the celebrities themselves. Mila Kunis. Daisy Ridley. Zoe Saldaña. Brooklyn Decker. The cap table is the credibility moat, entrenched before the brand has a single retail door.

The Milk Hair Serum is the hero product. 2026 revenue: $35M, profitable. 200+ Sephora doors. 300+ salons. Credo, Nordstrom, Goop.

Silas Capital, who led the seed, has seen this model before, they backed Makeup by Mario, the makeup artist-founded brand that followed the same professional-credibility-to-consumer playbook. L Catterton is now in, following their Remedy investment earlier this week.

Imagine a DTC instant coffee brand scaling to a $70M run rate in under two years, profitably.

That's the headline. But Reformed wouldn't call themselves a coffee brand, and the distinction is important.

Reformed is a supplement brand with a coffee and matcha anchor. A coffee pouch carrying 15g of collagen or 5g of creatine, plus 21 vitamins, lion's mane, chaga, and MCT oil. Around $53 a month. This week they closed a $22.5M Series A led by Iris Ventures, two years after launch.

The model is habit stacking, one of the most bankable consumer investment trends of the year. Instead of forcing consumers to adopt an entirely new health behavior or remember to take a handful of pills, Reformed simply adopted a daily ritual 200 million people already perform and fundamentally upgraded what's inside the mug.

The credibility isn't a founder's professional background here, it's the credibility of the habit itself. Morning coffee has 40 years of daily compliance built in. Reformed borrowed that trust and added clinical-grade ingredients on top.

The growth curve reflects it: $10M in revenue in 2025, $70M run rate by mid-2026. US launch later this year.

Kieran Mathew sent 25 to 30 cold emails to a founder he'd never met. Not because he was looking for a job. Because he'd found a product he believed in and couldn't stop thinking about the opportunity hiding inside a small business nobody else was paying attention to.

Anthony Gustin eventually replied. That email turned into a conversation. The conversation turned into a partnership. And Equip Foods went from low seven figures to well into eight, largely without Meta spend, built instead on thousands of affiliate partners who became genuine evangelists for a brand they actually used.

The product made that possible. Equip makes animal-based protein built around one standard: real food ingredients, nothing the brand wouldn't stand behind completely. No fillers. No shortcuts. A product for a customer who reads labels and doesn't forgive compromises. That ingredient credibility is the reason the affiliate flywheel worked, thousands of partners seeding the product into the right communities, training the algorithm before a dollar of paid spend hit the platform. By the time Meta turned on, the creative was proven and the audience was already warm.

Beef protein did the rest. While the whey category faces margin compression and commoditization, the animal-based consumer is moving in the opposite direction; more loyal, more engaged, more willing to pay a premium for a brand that shares their values.

Three things from the conversation worth taking with you:

What it actually looks like to join a business as an operator rather than a founder. Kieran came in to scale something already working, which requires a fundamentally different mindset than starting from scratch. Knowing what not to break is as important as knowing what to build.

How to take over day-to-day functions without breaking what's already working. The early-stage flywheel that built Equip to seven figures was affiliate-led and community-driven. Introducing paid media without disrupting that organic engine required careful sequencing, the lessons are specific and transferable.

Why the org structure that got you to $3M won't get you to $15M. The team, the processes, and the decision-making model that works at one stage actively resists the next. Recognizing where those inflection points are before you hit them is the whole job.

🎧 Watch on YouTube, listen on Spotify.

Thanks to sponsors:
⚙️ Visit Patrol - simplified ADA compliance for Shopify merchants
🧾 Check out Aftersell - boost AOV and increase sales
✈️ Go to Ecommerce Equation - coaching brands on systems that work

In 2023, a private equity firm bought Care Bears for approximately $100 million.

The Weiss family had owned the brand for 40 years. In that time, Care Bears generated $12 billion in lifetime retail sales. They sold for $100M.

IVEST Consumer Partners reframed it from a children's entertainment business into a consumer products licensing company. Same asset. Different business model. Revenue 4x'd in three years. Now ABG is acquiring it.

That gap, $12B in lifetime retail sales, $100M family exit price, is the entire thesis of one of the most interesting investment trends in consumer right now. IP monetization has become one of the most attractive asset classes in alternative investments. And most people haven't noticed.

Why it works. The best IP assets share four characteristics: cultural equity that predates the commercial opportunity; the awareness exists, the monetization hasn't caught up. Asset-light licensing as the business model, the IP owner collects royalties, operators bear all the risk. Institutional capital as the unlock, family owners and founders systematically undermonetize. And an exit to an even larger licensing machine.

The margin profile is what attracts the capital. ABG generates 70%+ EBITDA margins on licensing revenue. No inventory. No manufacturing. No retail execution risk. In a world where physical retail is struggling and operating leverage is hard to find, pure IP licensing is one of the highest-margin consumer business models that exists.

The playbook in three case studies.

Cocomelon / Moonbug: A former Disney exec started buying YouTube children's channels. Little Baby Bum for $9M in 2018. Cocomelon and Blippi together for $120M. The strategy: take the brands beyond YouTube into Netflix, Disney, merchandising, licensing, live entertainment. By end of 2021: $100M EBITDA. Blackstone-backed Candle Media paid $3B. From $9M for the first acquisition to a $3B exit in under four years. Cocomelon isn't valuable because it produces episodes. It's valuable because it has an unbreakable emotional relationship with every toddler who has watched it, and the parents who buy the merchandise.

Care Bears / IVEST / ABG: Same thesis applied to heritage character IP. 85% global brand awareness. 190 countries. $12B in lifetime retail sales. Owned by a family that treated it as an entertainment business rather than a licensing machine. IVEST paid ~$100M. Reframed the model. 4x revenue in three years. $750M+ in retail sales projected for 2026. Now ABG, the second largest licensor globally after Disney, is acquiring it to run through their 1,700+ partner licensing infrastructure.

Bluey / BBC Studios: The most interesting current case study because the monetization is still in its early stages. Children and their parents spent 43.9 billion minutes watching Bluey in 2024. The most streamed show in the United States. The fastest-growing licensed book brand in the US with 14.5M+ books sold. The No. 2 preschool toy property in the US. And, the detail that deserves more attention than it gets, Disney announced that Bluey would become the first non-Disney owned brand to feature at its Disneyland and Disney World parks. Disney doesn't share that real estate. Ever. The fact that Bluey is in is the clearest possible institutional validation of the IP's tier. The biggest value event is still ahead: a 2027 theatrical feature film that will introduce Bluey to millions of new consumers simultaneously.

The pattern running through all three: the creators built the cultural equity. The institutions with commercial infrastructure captured the economics. Ludo Studio created Bluey. BBC Studios licensed it. The Weiss family built Care Bears for 40 years. IVEST extracted the value they left behind.

The IP monetization wave is real. The returns are documented. The playbook is repeatable. The question nobody has answered publicly yet: does it compound forever, or does it eventually decay?

Bluey's 2027 feature film. ABG's IPO. Care Bears under ABG's licensing machine. The next 18 months will tell us.

Quick ask this week:

I’m always trying to make this newsletter more useful. Too long? Too short? A category or story you want covered? Or something you’re building in consumer you want to talk about? Email me directly - I read and reply to everyone.

Email: [email protected]
LinkedIn: linkedin.com/in/fanbi/